Search

The craking of squalene was studied with and without heterogeneous catalysts. The thermal decomposition of squalene occurred suddenly as a chain reaction above 723 K, yielding linear C5 (isoprene) and C10 hydrocarbons selectively with a conversion of >90%. The decomposition mechanism may involve allyl bi-radicals, ˙CH2–C(CH3)CH–CH2˙, intermediates that convert to isoprene, CH2C(CH3)–CHCH2.

Significance Peter D. Mitchell, a Nobel awardee in 1978, proposed that F o F 1 -ATP synthase converts energy between electrochemical potential of H + across biological membrane ( Δ μ ∼ H + ), which is established by respiratory chain complexes, and chemical potential of adenine nucleotide [ΔG (ATP) ]. However, the efficiency of the energy conversion has been a matter of debate for over 50 years. In this study, with a highly reproducible analytical system using F o F 1 -ATP synthase from thermophilic Bacillus , apparently perfect energy conversion was observed. Mitchell’s prediction thus has quantitative evidence.

A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model.

Morphological control of poly(2,5-benzimidazole) (PBI) was examined by reaction-induced phase separation of oligomers during polymerization to prepare nanofibers. Three monomers, 3,4-diaminobenzoic acid (DABA), 3,4-diacetoamidebenzoic acid (DAcBA) and phenyl 3,4-diaminobenzoate (PDAB), were used to synthesize PBI. Polymerizations were carried out at 350 °C in a mixture of dibenzyltoluene isomers. Polymerization of DABA yielded spheres with plate-like crystals on their surface. Polymerization of DAcBA yielded almost no precipitates because of the high solubility of DAcBA oligomers. By contrast, polymerization of PDAB yielded aggregates of PBI nanofibers (of which the average diameter was ∼60 nm), which resembled nonwoven fabrics. These fibers were formed by precipitation of (2,5-benzimidazole) oligomers and their subsequent polymerization into a developing crystal structure. The structure of the monomer significantly influenced the morphology of the PBI product, and PDAB was preferable for the preparation of PBI nanofibers. The temperature of 10% N2 weight loss in these nanofibers was in the range of 634–644 °C and they were thermally stable. The network aggregates of poly(2,5-benzimidazole) nanofibers were prepared by the polymerization of phenyl 3,4-diaminobenzoate at 350 °C in a mixture of dibenzyltoluene isomers. The average diameter of the fibers was ∼60 nm. These fibers were formed by the crystallization of oligoimidazoles and the subsequent polymerization in them.

Poly[2,6-(1,4-phenylene)-benzobisimidazole] (PPBI) crystals were prepared by using reaction-induced crystallization of oligomers during solution polymerization of 1,2,4,5-tetraaminobenzene and diphenyl terephthalate. Polymerizations were carried out at a monomer concentration of 4.3 × 10−2 mol L−1 at 350 °C for 6 h. Brush-like PPBI crystals were obtained in a mixture of structural isomers of dibenzyltoluene, in which many needle-like crystals came out vertically from the surface of the ribbon-like crystals. Average width and thickness of the ribbon-like crystals were 0.75 μm and 0.11 μm, respectively. And average length and diameter of the needle-like crystals were 0.36 μm and 50 nm, respectively. The brush-like crystals possessed high crystallinity and exhibited good thermal resistance. The ribbon-like crystals were formed by the crystallization of imidazole oligomers at an initial stage of polymerization, and then the needle-like crystals grew from the surface of the ribbon-like crystals. Polymerization occurred on the crystals when the oligomers were crystallized, leading to the high molecular weight PPBI crystals.

Mitemcinal is an erythromycin derivative with motilin agonistic action, developed as a gastrointestinal motor-activating agent. The characteristics of mitemcinal-induced multinuclear hepatocytes (MNHs, hepatocytes with three or more nuclei per cell) from detailed morphological observations together with the results of a study on the mechanisms of MNH formation by combining cytocentrifuge preparations with 5-bromo-2’-deoxyuridine cumulative labeling are reported. MNHs were observed only in rats in the high-dose groups of the subchronic study, with a higher incidence in females and reversibility after twenty-eight days of drug withdrawal, but not observed in dogs. In the chronic study, the incidence increased relative to the dose. Histopathologically, MNHs were preferentially observed in the centrilobular zone, without nuclear atypia or mitotic figures. In the cell kinetic study, the labeling pattern of MNHs included all-positive, all-negative, and mixed labeling patterns of nuclei. The all-negative pattern indicated that the cells were formed by fusion of nondividing cells. The current results indicate that the cell kinetic approach effectively demonstrated the mechanism of mitemcinal-induced MNHs as fusion of hepatocytes and that drug-induced disturbance of mitosis is not involved in the multinucleation of MNHs by mitemcinal.

Morphology control of polybenzimidazoles was examined by reaction-induced phase separation during polymerization. Polymerizations of 3,3′-diaminobenzidine with terephthalic acid or diphenyl terephthalate were carried out in poor solvents. The morphology of the precipitated poly[2,2′-(1,4-phenylene)-5,5′-bibenzimidazole] (PpBBI) was significantly influenced by the polymerization conditions, and the aggregates of nano-scale PpBBI fibers were obtained by the polymerization at a concentration of 3–5% and 320–350 °C in dibenzyltoluene. The average diameter of the fibers was ca. 50 nm and inherent viscosities of the precipitates were 0.35–0.58 dL g −1 . They possessed high crystallinity and thermal stability. The oligomers were precipitated first by the reaction-induced crystallization to form the highly crystalline lath-like crystals at an initial stage of polymerization. Then the lath-like crystals were split into disentangled aggregates of fine fibers with maintaining the high crystallinity. The polymerization mainly proceeded when the oligomers were registered into the crystals. The obtained aggregates of nano-scale fibers could be recognized as nonwoven fabrics. Morphology control of poly[2,2′-(1,3-phenylene)-5,5′-bibenzimidazole] was also examined and particles were mainly formed.

Mitemcinal is an erythromycin derivative, which acts as an agonist of the motilin receptor. For assessment of the carcinogenicity of mitemcinal, we conducted a short-term carcinogenicity study in p53 (+/-) C57BL/6 mice and a 104-week carcinogenicity study in CD(SD)IGS rats. There was no evidence of a carcinogenic potential in mouse when administered for 26 consecutive weeks at levels up to 250 mg/kg/day. In the rat study, an increased incidence of lymphoma was noted in 5/60 males and 8/60 females of the high dose group (60 mg/kg/day) compared to 1/60 and 0/60 in control males and females, respectively, with statistical significance in females. Rat lymphomas include different immunomorphologic types (T- or B-cell lineage). Immunohistochemical analysis revealed that lymphomas from mitemcinal-treated rats and spontaneous cases were of T-cell lineage. The overall weight of evidence suggests that the incidence of spontaneous lymphoma was enhanced in the rat study. They also indicate that the increased incidence of lymphomas was based on a non-genotoxic effect with a threshold dose-response and that the tumorigenesis was based on the strain or species specificity of background factors. The high dose in the rat study is approximately 1600-fold higher (AUC) than that of the clinical dose, a sufficient margin of safety for the clinical dose. We conclude that the risk of carcinogenesis due to mitemcinal in humans can be considered to be minimal and is to represent an acceptable risk for the continued administration of mitemcinal to humans.

Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor. Erythromycin has shown QT prolongation and torsades de pointes (TdP) in humans and cisapride, a second class of prokinetic agents typified by the 5-HT(4) receptor agonist, has been terminated due to TdP. In this study an extended series of safety pharmacology protocols and evaluations have been undertaken to assess the potential risk of mitemcinal on QT prolongation or proarrhythmic effects. Mitemcinal and its metabolites, GM-577 and GM-625, inhibited the human ether-a-go-go-related gene (HERG) tail current in a concentration-dependent manner with IC(50) values of 20.2, 41.7, and 55.0 microM, respectively. Administration of 10 mg/kg mitemcinal in anesthetized guinea pigs resulted in a slight prolongation of the monophasic action potential (MAP) duration during atrial pacing at the plasma concentration of mitemcinal 1.1 microM, with low maximum increases in MAPD(70) (6.6%) and MAPD(90) (4.6%) relative to vehicle. A 10-min infusion of 20 mg/kg of mitemcinal in a proarrhythmic rabbit model did not evoke TdP even when QT and corrected QT (QTc) intervals were significantly prolonged. In this study, the Cmax plasma-free concentration of mitemcinal indicates that the prolongation was more than 400-fold that of the therapeutic dose. Our findings of a wide safety margin and the absence of TdP within this margin suggest that mitemcinal may provide sufficient safety in clinical use.

Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor. We investigated the QT-prolonging effects of mitemcinal using a halothane-anesthetized canine model. Intravenous administration of mitemcinal at doses of more than 8.3 mg/kg per 10 min significantly prolonged the QT interval corrected by Fridericia's corrections. Mitemcinal exhibited a bradycardiac effect and produced significantly greater prolongation in monophasic action potential duration (MAP(90)) at sinus rhythm compared with MAP(90) at pacing and showed reverse use-dependent prolongation of repolarization, suggesting that the negative chronotropic effect of mitemcinal potentiates the prolongation of the repolarization period. A technique using MAP/pacing electrodes allowed measurements of both MAP(90) and effective refractory period (ERP) simultaneously at the same ventricular site. Although mitemcinal slightly prolonged the MAP(90(CL400)) and ERP in comparison with the control group at the dose of 25 mg/kg per 10 min, the terminal repolarization period, the difference between MAP(90(CL400)) and ERP, did not increase suggesting the absence of a proarrhythmic effect even with a 7000-fold for the therapeutic blood concentration as free level. The electrophysiological results from mitemcinal in this study indicate that the risk of serious arrhythmia such as torsades de pointes, a major clinical concern related to QT interval prolongation, might be low.

Infrared Fabry–Perot filters were fabricated by stacking two silicon plates etched in KOH solution. When we applied a voltage between the plates, the spacing between them was decreased by an electrostatic force, which caused a shift in interference wavelength. The silicon plates were etched to 34 µm thickness to reduce the driving voltage. When the voltage was increased from 0 to 20 V, the wavelength of the interference peak shifted from 7.9 to 5.5 µm, corresponding to the decrease in the spacing from 7.9 to 5.5 µm. The peak transmittance increased to ~90% by coating an antireflection film on the outer surface of the filter. This coating was effective in suppressing the interference inside the silicon plates, which created a complicated spectrum.

Dynamics of phase separation induced by polymerization of 2-chlorostyrene in the presence of polystyrene was studied by an scanning electron microscope and a time-resolved light scattering instrument with varying initial monomer composition θ in the range from 0.4 to 0.6. Phase-separation rate increased with increasing θ or temperature. Phase being rich in poly(2-chlorostyrene) formed droplets initially and these droplets coagulated to form continuous domains at low temperatures. A maximum was found in the initial-composition dependence of the time when morphological change from droplets to continuous domains occurred. Qualitative discussion was made for the effects of initial composition change on morphological change of poly(2-chlorostyrene)-rich phase.

We developed a new method for the synthesis of an organic-soluble insulated molecular wire (IMW) with permethylated cyclodextrin (PMCD); this method involves click polymerization of linked [2]rotaxane containing azide and alkynyl groups at both ends of a π-conjugated guest.

We previously described two different water absorption systems in the ventral skin of the Japanese tree-frog, Hyla arborea japonica: i.e., a rapid enhanced flow, which is observed in dehydrated tree-frogs or those stimulated by adrenaline beta-agonists or vasotocin, and a slow basal flow, which is observed in normally hydrated frogs during the non-breeding season. The rapid flow is completely blocked by ouabain, which has no effects on the slow basal flow. In the present experiment, we show that the vaso-constrictive hormone angiotensin II completely inhibits basal water absorption, but has no effect on rapid water absorption. These results confirm our previous finding that the two water absorption systems in the ventral skin of the Japanese tree-frog are independent of each other.

Background: We hypothesized that the androgen receptor (AR) pure antagonists, which exhibit no agonist activities, would inhibit AR signaling completely and would be efficacious against castration-resistant prostate cancer (CRPC). Based on our understanding of estrogen receptor pure antagonists, we designed dihydrotestosterone (DHT) derivatives and nonsteroidal RU56187 derivatives that inhibit the folding of helix 12 of AR and screened AR pure antagonists. Although a non-steroidal derivative (CH4933468) showed improved metabolic stability compared with DHT derivatives, it metabolized into an extremely small amount of a dealkylated metabolite with strong agonist effect. Therefore, CH4933468 did not show antitumor activity against the CRPC xenograft model. Methods: For metabolic stability, we designed and synthesized sulfonamide-substituted aryl compounds without dealkylated agonist metabolites. The production of agonist metabolites was examined in rat, mouse, monkey and dog. The efficacy of our compounds was measured using an in vitro reporter assay, a cell growth assay and in vivo prostate cancer xenograft models. Results: As a result of our optimization, CH5137291 was discovered and found to be an orally-active androgen receptor pure antagonist without agonistic activities derived from dealkylated agonist metabolites in vivo in rat, mouse, monkey and dog. CH5137291 exhibited AR antagonistic activities of IC50 of 300 nM and no agonist activity even at 30,000 nM in the reporter gene assay. In LNCaP-BC2 cells (AR overexpression CRPC model), CH5137291 was more efficient than bicalutamide. CH5137291 completely inhibited cell growth, in contrast to the partial inhibition of bicalutamide. Furthermore, CH5137291 inhibited the tumor growth and PSA production in the LNCaP-BC2 xenograft model. CH5137291 also inhibited AR nuclear translocation in the presence of R1881. According to the binding models of CH5137291 and bicalutamide to wild type AR, the sulfonamide of CH5137291 directly collided with M895 and thus prevented the folding of helix 12 completely. On the other hand, bicalutamide did not collide with M895 from helix 12 and inhibited helix 12 folding indirectly through W741. Hence, CH5137291 might act as an AR pure antagonist, but bicalutamide apparently does not. Conclusions: CH5137291, a novel AR pure antagonist without agonistic activities derived from dealkylated agonist metabolites, has shown antitumor activities in both in vitro and in vivo CRPC models. Our experimental results for clinical candidate CH5137291 corroborate our hypothesis that pure antagonists inhibit the folding of helix 12 completely, leading to the complete inhibition of the transcription activity of AR. Based on the strong efficacy against CRPC xenograft model and the inhibition of AR nuclear translocation, CH5137291 may offer more benefit than bicalutamide. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A220.

Polarized photoluminescence (PL) spectra were measured in single crystal of SrGa2S4:Ce prepared by chemical vapor transport technique. A PL band with double peaks at 450 and 493 nm showed strong polarization dependence in shapes and intensities between E∥c and E⊥c polarizations. The PL spectra have been discussed in the framework of the crystal-field theory by which the two peaks have been assigned to transitions between crystal-field and L-S coupling multiplets of 5d- and 4f-states of Ce3+ in D4h symmetry. Polarized PL spectra calculated on the basis of the crystal-field theory show good agreement with the experimental ones. From these results we suggest a possibility of controlling the chromaticity in blue electroluminescent (EL) phosphors using epitaxial films with well-defined growth orientation.